Abstract: A method for social group data management is provided. The method includes a server receiving a social group setup requirement and first user information from a first user terminal, and generating a social group list in responding to the social group setup requirement, where the social group list includes the first user information; the server receiving a social group joining requirement and second user information from a second user terminal, and adding the second user information into the social group list in responding to the social group joining requirement; the server receiving a social group leaving requirement from the second user terminal, and transmitting the social group leaving requirement to the first user terminal; and the server receiving a permitting message from the first user terminal, and deleting the second user information in the social group list in responding to the permitting message.

Abstract: A data sharing system includes a first sharer terminal, a receiver terminal and a service server. The service server is configured to receive a first sharer identity data, a first sharing command and a identity verification which is one of a share characteristic and a first shared data from the first sharer terminal. The service server, according to the first sharer identity data, the first sharing command and a share request, adds a new share list, or saves, modifies, or deletes at least one share list saved in a list storage module.

Abstract: The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.

Abstract: The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20 (pegylated ADI derived from M. hominis), but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.

Abstract: A data sharing system includes a first sharer terminal, a receiver terminal and a service server. The service server is configured to receive a first sharer identity data, a first sharing command and a identity verification which is one of a share characteristic and a first shared data from the first sharer terminal. The service server, according to the first sharer identity data, the first sharing command and a share request, adds a new share list, or saves, modifies, or deletes at least one share list saved in a list storage module.

Abstract: The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.

Abstract: The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.

Abstract: The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.

Abstract: A plasma display apparatus and a method of driving the same are disclosed. The plasma display apparatus includes a driver supplying a first signal and a second signal to a scan electrode during a reset period of at least one of a plurality of subfields of a frame. The first signal gradually rises from a first voltage to a second voltage with a first slope, and then falls from the second voltage to a third voltage with a second slope. The second signal rises from the third voltage to a fourth voltage, and then gradually rises from the fourth voltage to a fifth voltage with a third slope.

Abstract: A hydraulic circuit for heavy construction equipment to reduce a speed of a swing apparatus while a working apparatus such as a boom is concurrently operated has a work control valve which controls a working apparatus cylinder; a confluence valve which combines a hydraulic fluid of the second hydraulic pump with the work unit flow path based on a positions switch; a swing control valve which controls the hydraulic swing motor; and a disconnection valve which disconnects the hydraulic fluid supplied to at least one of the swing motors.

Abstract: The present invention relates to a plasma display apparatus, and more particularly, to a plasma display apparatus for preventing Electromagnetic Interference (EMI). The plasma display apparatus of the present invention comprises a plasma display panel comprising an electrode, and at least one of a first capacitor connected between a sustain voltage source for supplying a sustain voltage to the electrodes and a first ground voltage source, a second capacitor connected between a scan voltage source for supplying a scan voltage to the electrodes and a second ground voltage source, and a third capacitor connected between a set-up voltage source for supplying a set-up voltage to the electrodes and a third ground voltage source.

Abstract: A plasma display apparatus, and more particularly, a driving method and improved structure of a plasma display apparatus are provided. A sustain signal that alternates between a positive polarity and a negative polarity is supplied to only one electrode. Therefore, it can facilitate the adoption of an integrated driving board. Furthermore, a voltage magnitude of a set-up signal supplying in any one of the remaining sub-fields other than a first sub-field of a frame is less than the voltage magnitude of the set-up signal supplying in the first sub-field. It is therefore possible to increase the contrast.

Abstract: A plasma display panel for adaptively reducing load effect and improving luminescence efficiency and discharge efficiency, and a driving method thereof. A plasma display panel includes a capacitive load; a source capacitor; a sustain voltage source to generate a sustain voltage; a first inductor formed on a first current path where a current flows from the capacitive load to the source capacitor; a second inductor formed on a second current path where a current flows from the source capacitor to the capacitive load; a switch configuration and switch control circuit that controls the switching operations of the switch configuration such that at least two discharges may occur during one sustain pulse cycle.

Abstract: The present invention is related to a method of fabricating a rigid-flexible printed circuit board. Specifically, this invention relates to a method of fabricating a rigid-flexible printed circuit board, in which an internal circuit pattern exposed for use in an external pad and a mounting pad is protected from external environments using a resist cover by window etching the base copper foil of a flexible region upon formation of an external circuit pattern as opposed to using a resist cover. Thus the number of fabrication processes and the fabrication costs are decreased and the increase in defect rates due to contamination is prevented, resulting in maximized reliability.

Abstract: A pharmaceutical composition for the treatment of athetoid movement comprising clonazepam or pharmaceutically acceptable salts thereof as an active ingredient are provided, and are useful for the treatment of athetoisis without any tolerance and adverse effect.

Abstract: An automatic dose infusion apparatus that electronically controls a medicinal substance storage chamber and a control chamber, electronically regulates infusion of the medicinal substance, and constantly maintains a prescribed amount of medicinal substance on the basis of the number of rotations of a motor. The automatic dose infusion apparatus comprises a housing having three compartments, a medicinal substance storage chamber formed in the upper compartment of the housing for storing a medicinal substance pack, a control chamber formed in the middle compartment of the housing, a driving chamber formed in the lower compartment of the housing, a bolus switch connected to the housing for generating an additional medicinal substance infusion command signal, and a tube extending from the inside of the driving chamber to the outside of the driving chamber for delivering the medicinal substance discharged from the medicinal substance pack to a needle.